Impact of Site Enablement Platforms on Reducing C02 Emissions Report
Reducing the carbon footprint of clinical trials is crucial for the pharmaceutical industry. The Impact of Site Enablement Platforms on CO2 Emissions Report highlights the need for eco-friendly approaches to clinical trial management.
The report shows that Site Enablement platforms can:
- Reduce carbon emissions by up to 37.4% in a Phase III clinical trial.
- Cut CO2e emissions by 220.14 tons over a five-year trial period by enabling remote monitoring and reducing in-person visits by 50%.
- Reduce CO2e emissions by 15.49 tons associated with paper production and distribution by facilitating paperless operations.
- Help sponsors and CROs identify and select sites that are closer to patient populations, minimizing patient travel and associated emissions while making clinical trials more patient-centric.
- Improve data quality, compliance, and trial efficiency, leading to higher success rates, faster drug development, and a more patient-centric approach.
By implementing Site Enablement platforms and other eco-friendly approaches, the pharmaceutical industry can take significant steps toward mitigating its environmental impact while still advancing medical research. Don’t ignore the environmental consequences of clinical trials. Download the report now and start making a positive impact on the environment.
